Indivior Pharmaceuticals (INDV) vs Legend Biotech (LEGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Indivior Pharmaceuticals (INDV) has outperformed Legend Biotech (LEGN) over the past year, gaining 52.3% versus a loss of 39.1%. Over five years, INDV leads with a +127.9% price change compared with -63.2% for LEGN. Indivior Pharmaceuticals is the larger company by market cap ($4.24 billion vs $3.56 billion), about 1.2 times the size, while Legend Biotech is growing revenue faster (+64.0% vs +4.3%).
On valuation, Indivior Pharmaceuticals trades at a lower forward P/E (7.4x vs 17.4x for Legend Biotech). Indivior Pharmaceuticals converts more of its revenue into profit, with a net margin of 16.9% versus -28.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDV | LEGN |
|---|---|---|
| Share price | $35.94 | $18.30 |
| Market cap | $4.24B | $3.56B |
| 1-day change | -0.54% | -4.29% |
| YTD return | +0.70% | -12.05% |
| 1-year return | +52.32% | -39.13% |
| 5-year return | +127.95% | -63.17% |
| P/E ratio (TTM) | 12.88 | — |
| Forward P/E | 7.36 | 17.43 |
| EPS (TTM) | $2.79 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.24B | $1.03B |
| Revenue growth (YoY) | +4.29% | +64.04% |
| Net income (latest FY) | $210.00M | $-296.80M |
| Gross margin | 80.23% | 61.41% |
| Operating margin | 21.15% | -13.27% |
| Net margin | 16.95% | -28.85% |
| 52-week high | $42.81 | $37.50 |
| 52-week low | $22.95 | $16.24 |
| Distance from 52-week high | -16.06% | -51.20% |
| Analyst consensus | none | buy |
| Avg. price target upside | +36.36% | +154.09% |
| Average volume | 2.08M | 2.36M |
| Shares outstanding | 118.03M | 194.49M |
| Employees | 827 | 3,200 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDV has outperformed LEGN by 91.4 percentage points over the past year.
- Indivior Pharmaceuticals is more profitable, keeping 16.9 cents of every revenue dollar as net income versus -28.8 cents for Legend Biotech.
- Legend Biotech grew revenue faster in its latest fiscal year (+64.04% vs +4.29%).
About Indivior Pharmaceuticals
INDV stock →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
INDV vs LEGN FAQ
Which is bigger, Indivior Pharmaceuticals or Legend Biotech?
Indivior Pharmaceuticals (INDV) is larger, with a market capitalization of $4.24B compared with $3.56B for Legend Biotech (LEGN).
Which stock has performed better over the past year, INDV or LEGN?
INDV returned +52.32% over the past 12 months, compared with -39.13% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are Indivior Pharmaceuticals and Legend Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.